Table 1. Pharmacokinetic parameters of the different mAbs and rates of infection after mucosal SHIV challenge of rhesus macaques.

Each mAb was given at the indicated dose intravenously to rhesus macaques, and the level of antibody in the plasma was quantitated by an antibody-specific ELISA using the cognate antigen. Values for concentration of mAb and half-life are the means ± SEM. The plasma half-lives were calculated using the WinNonlin software.

Antibody
(no. of animals)
Antibody dose
(mg/kg)
Concentration at day of
challenge (μg/ml)
Half-life (days)Challenge virus (route)Rate of infection
mAb2D5 (4)40351.6 ± 16.61.2 ± 0.1SHIV SF162P3 (rectal)2/4
VRC01 (4)2079.2 ± 2.37.0 ± 0.3SHIV SF162P3 (rectal)0/4
VRC01 (4)2064.6 ± 7.05.3 ± 1.4SHIV SF162P3 (vaginal)0/4
VRC01 (6)2060.9 ± 2.46.8 ± 1.6SHIV BaLP4 (rectal)0/6
10E8 (6)20133 ± 5.53.2 ± 0.7SHIV BaLP4 (rectal)0/6
PG9 (6)2032.0 ± 3.02.2 ± 0.4SHIV BaLP4 (rectal)2/6
VRC01 (6)522.2 ± 1.48.3 ± 2.3SHIV BaLP4 (rectal)0/6
10E8 (6)531.3 ± 1.85.5 ± 1.4SHIV BaLP4 (rectal)0/6
PG9 (6)53.7 ± 0.22.2 ± 0.1SHIV BaLP4 (rectal)3/6
VRC01 (10)0.31.3 ± 0.15.1 ± 0.8SHIV BaLP4 (rectal)6/10
10E8 (6)0.31.8 ± 0.166.9 ± 0.7SHIV BaLP4 (rectal)3/6
PG9 (6)0.30.28 ± 0.033.2 ± 0.5SHIV BaLP4 (rectal)6/6